US and Japan plan next Think Tank on expediting cardio device approvals
This article was originally published in Clinica
January 2007 will see the next work phase of a US/Japan think tank that is designed to address the concept of global clinical trials and examine regulatory barriers that may be impediments to timely cardiovascular device approvals. Durham, North Carolina will be the host location of "HBD Think Tank West", which will take up where the Tokyo, Japan-hosted "HBD Think Tank East" - the inaugural session in this programme - left off in December 2005.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.